TELA Bio, Inc.

For the period ended Dec 31, 2025. Filed Mar 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 25, 2026

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)


· · Year ended December 31,
· · 2025 · · 2024 · · 2023
Revenue	$80,275	$69,300	$58,453
Cost of revenue (excluding amortization of intangible assets)	25,554	22,432	17,961
Amortization of intangible assets	380	380	380
Gross profit	54,341	46,488	40,112
Operating expenses:
Sales and marketing	63,182	64,648	59,681
General and administrative	15,694	14,722	14,887
Research and development	9,220	8,813	9,619
Total operating expenses	88,096	88,183	84,187
Other operating income:
Gain on sale of product line	—	7,580	—
Loss from operations	(33,755)	(34,115)	(44,075)
Other (expense) income:
Interest expense	(5,245)	(5,290)	(5,223)
Loss on extinguishment of debt	(888)	—	—
Other income	1,287	1,420	2,634
Total other expense, net	(4,846)	(3,870)	(2,589)
Loss before income tax (expense) benefit	(38,601)	(37,985)	(46,664)
Income tax (expense) benefit	(230)	144	—
Net loss	$(38,831)	$(37,841)	$(46,664)
Net loss per common share, basic and diluted	$(0.83)	$(1.33)	$(2.04)
Weighted average common shares outstanding, basic and diluted	46,947,932	28,526,441	22,868,663
Comprehensive loss:
Net loss	$(38,831)	$(37,841)	$(46,664)
Foreign currency translation adjustment	1	(1)	(59)
Comprehensive loss	$(38,830)	$(37,842)	$(46,723)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.